Effects of Low-Doses Aspirin on Clinical Outcome and Disease Progression in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results of a Multicentric Retrospective Study
#1823
Introduction: The chemopreventive effect of aspirin (ASA) have been observed in the setting of colorectal cancer. The impact of aspirin use on clinical outcome of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP NEN) has not been evaluated yet
Aim(s): To retrospectively evaluate the clinical outcome of GEP NEN patients treated with ASA
Materials and methods: All the GEP NENs patients followed up in three European Centres, from January 2005 to September 2016, were retrospectively enrolled. The possible association between ASA and disease grading, staging, primary site, overall OS and PFS were evaluated.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Cavalcoli F
Authors: Massironi S, Pusceddu S, Cavalcoli F, Zilli A, Tamagno G,
To read the full abstract, please log into your ENETS Member account.